Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10551152 | 0.98 | LMNA (0.38) | LMNAAPOBEC3AAPOBEC3GALDH1A1HSD17B10 | |
| SCHEMBL16700361 | 0.88 | ALDH1A1 (0.38) | LMNAAPOBEC3AAPOBEC3GALDH1A1BBOX1 | |
| SCHEMBL15820573 | 0.86 | LMNA (0.39) | LMNAAPOBEC3AAPOBEC3GALDH1A1BBOX1 | |
| SCHEMBL16701182 | 0.85 | LMNA (0.41) | LMNAAPOBEC3AAPOBEC3GALDH1A1 | |
| SCHEMBL623417 | 0.79 | LMNA (0.36) | LMNA | |
| SCHEMBL4246323 | 0.77 | — | — | |
| SCHEMBL2267527 | 0.76 | CHRM2 (0.30) | — | |
| SCHEMBL15209391 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL5801688 | 0.70 | CDC25A (0.40) | LMNAAPOBEC3AAPOBEC3G | |
| SCHEMBL20686931 | 0.69 | KDM4E (0.30) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150335547-A1 | ORAL CARE COMPOSITION CONTAINING IONIC LIQUIDS | COLGATE-PALMOLIVE COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2934469-A2 | ORAL CARE COMPOSITION CONTAINING IONIC LIQUIDS | Colgate-Palmolive Company (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014098871-A2 | ORAL CARE COMPOSITION CONTAINING IONIC LIQUIDS | COLGATE-PALMOLIVE COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335547-A1 | ORAL CARE COMPOSITION CONTAINING IONIC LIQUIDS | MCOLN3, TAS2R39, TAS2R40 | LMNA 1795/4885APOBEC3A 4021/4885APOBEC3G 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.